Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

T-OP

Financiado

Cerrado

Training Network for Optimizing Adoptive T cell Therapy of Cancer

Over the last years, immunotherapy – using a patient’s own immune system to fight tumours – has emerged as an important complement to standard treatments. The clinical implementation of immunotherapeutics has established T cells a... ver más

28/02/2025

LMU MUENCHEN

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 12 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2025-02-28

MSCA-ITN-2020: Innovative Training Networks Objective:The Innovative Training Networks (ITN) aim to train a new generation of creative, entrepre...

I+D

Cerrada hace 5 años

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

12 Participantes

LMU MUENCHEN

758.37K€ | Lider

IMM

303.17K€ | Participante

F. HoffmannLa Roche AG

281.28K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 54 meses Fecha Inicio: 2020-08-27
Fecha Fin: 2025-02-28

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Over the last years, immunotherapy – using a patient’s own immune system to fight tumours – has emerged as an important complement to standard treatments. The clinical implementation of immunotherapeutics has established T cells as efficient anti-cancer weapons if targeted by specific drugs. Their therapeutic utilization has recently come to a breakthrough: adoptive T cell therapy (ACT), collecting and transforming the patient’s own T cells to treat cancer. An estimated 753 different cell therapies are currently in development, of which 375 are in clinical trials worldwide. The global cell therapy market was valued at $2.70 billion in 2018 and is expected to reach $8.21 billion in 2025. While European pharmaceutical companies and research institutions rank amongst the world leaders in basic and preclinical aspects of immunity including cell therapy development, clinical innovations and approvals in this field have largely been pioneered in other countries, especially in the USA and in China. The generation of such ACT products is a complex but ill-defined process with limited harmonization across production and clinical studies, even for the same indication. Cytokines are proteins responsible for the growth and differentiation of T cells. They are central to the generation procedure, whilst also playing a key role in the efficacy and safety of the cellular product. There is however a limited understanding as to which cytokines might lead to the best outcome on any of these steps. T-OP targets a pioneering research question: how do cytokines influence the therapeutic outcome of ACT products? T-OP brings together interdisciplinary and cross-sectorial teams spanning large and small-sized companies as well as experts in different aspects of cell therapy, immunology, protein engineering and bioinformatics. T-OP will train by research 15 ESR, enabling them to develop efficient therapeutic solutions and to tackle economic opportunities.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores